New pill shows promise for rare kidney cancer in VHL patients
NCT ID NCT03401788
First seen Apr 14, 2026
Summary
This phase 2 trial is testing a daily pill called belzutifan in 50 people with VHL disease who have kidney cancer. The goal is to see if the drug can shrink tumors. Researchers are also monitoring how long any tumor shrinkage lasts and checking for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, Denmark
-
Cambridge University Hospital
Cambridge, United Kingdom
-
Hospital Georges Pompidou
Paris, France
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
Vanderbilt Medical Center
Nashville, Tennessee, 37232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Belzutifan (a pill taken once daily)
What this could lead to
If successful, belzutifan could become a new treatment option to shrink kidney tumors in people with VHL disease, potentially reducing the need for surgery.
What could go wrong
This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. The drug may not work for all patients or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.